Patient in China achieves complete remission from leukemia after CAR T-Cell therapy

In a landmark case in China, a middle-aged woman whose life was on the verge of ending was entirely cured of leukaemia through CAR T-cell therapy, with all cancer cells disappearing swiftly in what was described as the first study of its kind. Professor Qian Cheng, director of the Bio-Treatment Center at the hospital in Chongqing, confirmed that she was the first patient to have been entirely cured of the condition via gene therapy, a remarkable milestone given that leukaemia has been diagnosed in roughly four million people in China. The success of this case adds to the growing body of evidence supporting immune-mediated therapy, which was pioneered in the United States by scientists such as Dr. Carl June of the University of Pennsylvania and Dr. Michel Sadelain of Memorial-Sloan Kettering Cancer Center and is proving increasingly successful in human trials with thousands of patients worldwide.

CAR T-cell therapy works by using modified T cells to fight cancer cells in leukaemia patients, offering a meaningful advantage over conventional treatments such as chemotherapy and bone marrow transplants. Professor Qian noted that CAR T therapy can reduce treatment expenditures by at least 30 percent compared to bone marrow transplants while also being more likely to lead to a cure, making it a significantly more attractive option for patients. Six other patients receiving gene therapy at the same institution in Chongqing have also shown health improvements, and while CAR T gene therapy in China remains in the clinical trial stage with only ten hospitals across the country currently offering it, the encouraging results have motivated Professor Qian's team to continue researching optimal doses in order to further develop this novel treatment approach.